Related Experiment Video
Updated: Jul 9, 2026

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
Published on: March 29, 2024
The cholesterol paradox in heart failure
Periaswamy Velavan1, Poay Huan Loh, Andrew Clark
1Cardiothoracic Centre, Liverpool, UK. drvelavan@hotmail.com
Insights
Patients with advanced heart failure (HF) often have low cholesterol, contrary to expectations. This article explores the cholesterol paradox in HF and statin mechanisms.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure (HF) is a significant condition often caused by coronary artery disease (CAD).
- Hypercholesterolemia is a primary risk factor for CAD.
- Paradoxically, advanced HF patients frequently exhibit low cholesterol, correlating with poor prognosis.
Purpose of the Study:
- To examine the cholesterol paradox in heart failure.
- To investigate the potential mechanisms of statins in HF patients.
Main Methods:
- Review of existing literature on heart failure, coronary artery disease, and cholesterol.
- Analysis of findings from major clinical trials like CORONA and GISSI-HF.
- Exploration of the pleiotropic effects of statins beyond cholesterol lowering.
Main Results:
- Low cholesterol levels in advanced HF are linked to a worse prognosis.
- Statins are known to reduce morbidity and mortality in CAD patients without HF.
- Large trials on rosuvastatin in HF (CORONA, GISSI-HF) are crucial for understanding outcomes.
Conclusions:
- The role of cholesterol in advanced HF requires further investigation.
- Statins may offer benefits in HF beyond lipid-lowering through other biological effects.
- Understanding these mechanisms is key to improving HF management.
Abstract:
Heart failure (HF) is a common and serious condition that is usually due to coronary artery disease (CAD). Hypercholesterolemia is a major risk factor for CAD but, paradoxically, patients with advanced HF often have low cholesterol, which is associated with a poor prognosis. Cholesterol lowering with statins reduces morbidity and mortality in patients with CAD who do not have HF and might also have improved outcome in patients with HF had they not been excluded from the reported trials. The results of large trials such as the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Insufficienza Cardiaca (GISSI-HF) study addressing the effects of rosuvastatin in HF are keenly awaited. In addition to cholesterol lowering, statins have other biologic effects that might be responsible for some of their favorable effects. This article examines this cholesterol paradox and possible mechanisms.
Related Concept Videos
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Cholesterol: Significance and Regulation
Considering cholesterol and...
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Heart Failure Drugs: Diuretics
Heart Failure III: Clinical Manifestations